### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Group Art Unit: 1647

Henry Chiu et al.

Examiner: Lorraine Spector

Serial No.: 10/614,853

Confirmation No: 5148

Filed: July 8, 2003

CUSTOMER NO: 09157

For: Compositions and Methods for the Treatment of Immune Related

Electronically filed on July 23, 2007

Diseases

# **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

#### Π 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

#### $\prod$ 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set Serial No.: 10/614,853 Filing Date: July 8, 2003

forth in 37 CFR  $\S1.17(p)$  or a statement as specified in 37 CFR  $\S1.97(e)$ , as checked below.

## [] 37 CFR §1.97(d)

 after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed and/or the fee paid.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

[X] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for (i) United States patent(s) and United States patent application publication(s) and (ii) additional documents that are marked with an asterisk (\*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR § 1.98(a)(2)(ii)]. See Final Rule 1287 OG (October 12, 2004). Additional documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. 60/394,485, filed July 8,2002 and benefit from the prior application is claimed in this application under 35 U.S.C §120. However, copies of any cited document will be provided in its entirety at the request of the Office.

Serial No.: 10/614,853 Filing Date: July 8, 2003

Page 3

A concise explanation of relevance of the items listed on PTO-1449	Α	concise	explanation	of relevance	of the items	listed on	PTO-1449	is:
--	---	---------	-------------	--------------	--------------	-----------	----------	-----

- [X] not given
- [] given for each listed item
- [] given for non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: July 23, 2007

Anna Gil, Ph.D.

Reg. No. 46,726

Telephone No. (650) 225-1571

Sheet	1	of	1
ובבנ		VI.	

FORM PTO-1449				U.S. Dept. of Commerce	Atty Docket No.	i	Serial No. 10/614,853		
				Patent and Trademark Office	Applicant				
		SCLOSURES CITED B			Chiu et al. Filing Date	Grou	· )		
(Us	se seve	eral sheets if necessary	() 		08 Jul 2003	1614			
				FOREIGN PATENT DOCUMENT	S		<del></del>		
xaminer nitials		Document Number	Date	Country	Class	Subclass	Transla Yes	Translation Yes No	
	8	WO99/14240							
			OTHER DISCLO	SURES (Including Author, Title, Date	Pertinent Pages, etc	c.)			
	9	Shi, "A Novel Cyt Immunomodulatory 275(25):19167-191	Activity." J. B:	Ligand Pair: Identification, Mo iological Chemistry, American 9 0)	Society of Biolog	rization a	sts, Balt	imore	
								<del>,</del>	
								<u></u>	
	-								
								<u> </u>	
				•					
Examine	er	<u> </u>			Date Considered				